| | 
Part, Chapter, Paragraph
1 I, 3. 4 | Available at: htt ~ ~Prioux F (1993): L’infecondité en
2 II, 4. 3 | 590-597.~ ~Sullivan, D. F. (1971): A single index
3 II, 5. 2. 5 | Poli A et al, 2008; Sacks F et al, 2001); the hypolipidemic
4 II, 5. 2. 6 | Djordjević BD, Dontas AS, Fidanza F, Karvonen MJ, Kimura N,
5 II, 5. 2. 6 | 256: 2823-2828.~Turnbull F; Blood Pressure Lowering
6 II, 5. 2. 7 | Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais
7 II, 5. 3. 9 | 3.8 References~ ~Berrino F, De Angelis R, Sant M, Rosso
8 II, 5. 3. 9 | Santaquilani M, Berrino F, EUROCARE Working Group (
9 II, 5. 3. 9 | Stiller C, Kaatsch P, Berrino F, Terenziani M, the EUROCARE
10 II, 5. 3. 9 | v28-v40.~ ~Micheli A, Berrino F, Paci E, Verdecchia A, Pierotti
11 II, 5. 3. 9 | P, Verdecchia A, Berrino F, Coleman M (2003): Cancer
12 II, 5. 3. 9 | 116-118.~ ~Parkin DM, Bray F, Ferlay J, Pisani P (2005):
13 II, 5. 3. 9 | Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli
14 II, 5. 4. 8 | Cunningham S, Sullivan F and Morris A (2001), on
15 II, 5. 4. 8 | Massi Benedetti M, Carinci F, Orsini Federici M (2006),
16 II, 5. 5.Int(10)| Myers F, McCollam A, Woodhouse A (
17 II, 5. 5.Int(12)| Östlin, M. Danielsson, F. Diderichsen, A. Härenstam
18 II, 5. 5.Int(15)| I, Prince MJ, Reischies F, Roelands M, Skoog I, Turrina
19 II, 5. 5. 3 | De Henauw S , Gottrand F , De Bourdeaudhuij I, Gonzalez-Gross
20 II, 5. 5. 3 | Ruhrmann S, Schultze-Lutter F, Salokangas RK, Linszen
21 II, 5. 5. 3 | Wrigley S, Jackson H, Judd F, Komiti A (2005): Role of
22 II, 5. 5. 3 | 1187-1194.~Nashef L, Walker F, Allen P, et al (1996):
23 II, 5. 5. 3 | by: Aldenkamp A, Dreifuss F, Renier O, et al) Boca Raton,
24 II, 5. 5. 3 | Elsevier, Amsterdam.~Ranzato F, Perini P, Tzintzeva E et
25 II, 5. 5. 3 | de Rijk MC, Grigoletto F, Melcon MO, Breteler MM,
26 II, 5. 5. 3 | Perissinotto E, Grigoletto F, Amaducci L, Inzitari D (
27 II, 5. 5. 3 | Benito-Leon J, Bermejo-Pareja F, Rodriguez J, Molina JA,
28 II, 5. 5. 3 | 251(3):340-345.~Bermejo F, Gabriel R, Vega S, Morales
29 II, 5. 5. 3 | A, Cabezas C, Rodriguez F, de Pedro-Cuesta J (2002):
30 II, 5. 5. 3 | Wait S, Moutard-Martin F, Dujardin M, Ziegler M (
31 II, 5. 5. 3 | Bartoloni A, Bartalesi F, Gamboa Barahon H, Giuffrida
32 II, 5. 5. 3 | Deuschl G, Forstl H, Henn F, Heuser I, Oertel W, Reichmann
33 II, 5. 5. 3 | Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman
34 II, 5. 6. 6 | C, Bolosiu HD, Breedveld F, Dougados M, Emery P, Ferraccioli
35 II, 5. 6. 6 | Lindsey S, Pincus T, Wolfe F (1992): The American College
36 II, 5. 6. 6 | Pillemer SR, Steen VD, Wolfe F (1998): Estimates of the
37 II, 5. 6. 6 | MA, de Regt EB, Andries F, van Agt HM, Bijl RV, de
38 II, 5. 6. 6 | Head J, Canner R, North F, Marmot M (1995): Sickness
39 II, 5. 7. 7 | 94):S28-S35.~Garcia-Lopez F. Epirce. Epidemiologia de
40 II, 5. 7. 7 | Hsu CY, Vittinghoff E, Lin F, Shlipak MG (2004): The
41 II, 5. 7. 7 | Otero A, Gayoso P, Garcia F, de Francisco AL (2005):
42 II, 5. 7. 7 | P, Vecchio LD, Locatelli F (2007): International Study
43 II, 5. 8. 7 | Corsico A, Sunyer J, Neukirch F, Kunzli N, Leynaert B, Janson
44 II, 5. 8. 7 | Jansson SA, Andersson F, Borg S, Ericsson A, Jonsson
45 II, 5. 8. 7 | Gingles J, Shepherd R, Kee F, Patterson C, MacMahon J (
46 II, 5. 8. 7 | Errico A, Urrutia I, Payo F, Olivieri M, Villani S,
47 II, 5. 8. 7 | G, Pedreschi M, Pistelli F, Di Pede F, Baldacci S,
48 II, 5. 8. 7 | Pedreschi M, Pistelli F, Di Pede F, Baldacci S, Carrozzi L,
49 II, 5. 9. 4 | male to female ratio (M:F) significantly narrowed
50 II, 5. 9. 7 | 1053.~ ~Baiardini I, Braido F, Brandi S, Canonica GW (
51 II, 5. 9. 7 | Allergy 62:301-9.~ ~Braido F, Baiardini I, Brandi S (
52 II, 5. 11. 3 | 2003; 49:107–108.~R Silva, F Pere a, O Bord o, E Silva,
53 II, 5. 11. 7 | 2003;30:123–131.~ ~Dalgard F, Svensson A, et al (2003):
54 II, 5. 11. 7 | S61):1-6.~ ~Ferlay J, Bray F, Pisani P, Parkin DM (2001):
55 II, 5. 11. 7 | Dermatitis 1985;13:29-48.~ ~Levi F, Te VC, Randimbison L et
56 II, 5. 12. 7 | Nainan OV, McQuillan GM, Gao F, Moyer LA,~Kaslow RA, Margolis
57 II, 5. 12. 7 | 777-782.~ ~Bsetti C, Levi F, Lucchini F, Zatonski WA,
58 II, 5. 12. 7 | Bsetti C, Levi F, Lucchini F, Zatonski WA, Negri E, La
59 II, 5. 12. 7 | 351.~ ~La Vecchia C, Levi F, Lucchini F, Franceschi
60 II, 5. 12. 7 | Vecchia C, Levi F, Lucchini F, Franceschi S, Negri E (
61 II, 6. 4. 5 | sanctions and reporting systems; f) phase out and replace antimicrobial
62 II, 7. 7 | K, Sharma G.~ ~Racioppi F, Eriksson L, Tingvall C,
63 II, 7. 7 | Shields N, Sethi D, Racioppi F, Yordi Aguirre I, Baumgarten
64 II, 8. 2. 1 | Haveman, M., Jørgensen, F., & O’Farrell, L., (2005).
65 II, 8. 2. 2 | Nucci C, Cedrone C, Culasso F, Ricci F, Cesareo M, Corsi
66 II, 8. 2. 2 | Cedrone C, Culasso F, Ricci F, Cesareo M, Corsi A and
67 II, 9. 1. 1 | C=core, R=recommended, F=for further development)~ ~
68 II, 9. 1. 1 | APGAR score at 5 minutes~F: Causes of perinatal death/
69 II, 9. 1. 1 | to congenital anomalies~F: Prevalence of cerebral
70 II, 9. 1. 1 | Prevalence of cerebral palsy~F: Prevalence of hypoxic-ischemic
71 II, 9. 1. 1 | hypoxic-ischemic encephalopathy~ F: Prevalence of late induced
72 II, 9. 1. 1 | late induced abortions~ F: Severe neonatal morbidity
73 II, 9. 1. 1 | among babies at high risk~ F: Neonatal screening policies~
74 II, 9. 1. 1 | severe maternal morbidity~F: Prevalence of trauma to
75 II, 9. 1. 1 | of trauma to the perineum~F: Prevalence of faecal incontinence~
76 II, 9. 1. 1 | Prevalence of faecal incontinence~F: Postpartum depression~Population
77 II, 9. 1. 1 | Distribution of mothers’ education~F: Distribution of mothers'
78 II, 9. 1. 1 | breast-feeding at birth~F: Indicator of support to
79 II, 9. 1. 1 | Indicator of support to women~F: Indicator of maternal satisfaction~
80 II, 9. 1. 1 | of maternal satisfaction~F: Births attended by midwives~
81 II, 9. 1. 1 | Births attended by midwives~F: Births without medical
82 II, 9. 1. 2 | following prenatal diagnosis f) linkage between different
83 II, 9. 1. 2 | specific genetic risks.~ ~f) The phenomenon of older
84 II, 9. 1. 2 | 369, pp 641-642.~Bianchi F, Bianca S, Linzalone N,
85 II, 9. 1. 2 | Ha M-C, Ayme S, Bianchi F, Calzolari E, De Walle H,
86 II, 9. 1. 2 | Feijoo M, Lillis D, Bianchi F (2005): "Trends and Geographic
87 II, 9. 2. 7 | 11, 313-326, 1976.~ ~Levi F, La Vecchia C, Negri E,
88 II, 9. 2. 7 | Vecchia C, Negri E, Lucchini F (2001): Childhood cancer
89 II, 9. 2. 7 | C, Johnson A, Alderdice F, Petty T, Macfarlane A (
90 II, 9. 3. 1 | Mazzeha, C. Keech. M. Hobbs, F.D.R. Fourcade R. Kiemeney ,
91 II, 9. 3. 1 | Falzon D and Belghiti F (2007): Tuberculosis – still
92 II, 9. 3. 1 | C, Johnson A, Alderdice F, Petty T, Macfarlane A (
93 II, 9. 3. 2 | Philibert M, Boisbras F, Bouvier-Colle M-H (2006):
94 II, 9. 3. 3 | 3.6. References~ ~Amaro F, Frazão C, Pereire ME, da
95 II, 9. 3. 3 | Ducot B, Johnson AM, Le Pont F, Wellings K, Spira A, Field
96 II, 9. 3. 3 | France.~Bochow M, Chiarotti F, davies P, Dubois-Arber
97 II, 9. 3. 3 | davies P, Dubois-Arber F, Dür W, Fouchard J, Gruet
98 II, 9. 3. 3 | Dür W, Fouchard J, Gruet F, McManus T, Markert S, Sandfort
99 II, 9. 3. 3 | 18 :1867-73.~Dubois-Arber F, Jeannin A, Konings E, Paccaud
100 II, 9. 3. 3 | Jeannin A, Konings E, Paccaud F (1997): Increased condom
101 II, 9. 3. 3 | Cousins G, Donnelly C, Mulcahy F, Conroy R (2006): The Irish
102 II, 9. 3. 3 | Health 35:298-305~Serbanescu F, Morris L, Marin M (2001):
103 II, 9. 4. 7 | Medicine; 3(3):94-98~ ~Mahar, F (2003): Sexually transmitted
104 II, 9. 5. 6 | Danielsson M, Diderichsen F, Härenstam A, Lindberg G).
105 II, 9. 5. 6 | C, Johnson A, Alderdice F, Petty T,Macfarlane A (1996):
106 II, 9. 5. 6 | Garamond Press Ltd.~ ~Myers F, McCollam A, Woodhouse A (
107 III, 10. 2. 1 | Kvinnsland S, La Vecchia C, Levi F, McVie JC, Maisonneuve P,
108 III, 10. 2. 1 | Newton Bishop J, Oleari F, Perrin P, Quinn M, Richards
109 III, 10. 2. 1 | B, Luczynska C, Neukirch F, Vermeire P, Wjst M and
110 III, 10. 2. 1 | A, Nilsson JA, Lindgarde F (2002): Prevention of alcohol-related
111 III, 10. 2. 1 | 484.~ ~Kunst AE, Groenhof F, Mackenbach JP, EU Working
112 III, 10. 2. 1 | Heimerson I, Diderichsen F (2005): Socioeconomic Differentials
113 III, 10. 2. 1 | 277.~ ~Kaner EFS, Beyer F, Dickinson HO, Pienaar E,
114 III, 10. 2. 1 | HO, Pienaar E, Campbell F, Schlesinger C, Heather
115 III, 10. 2. 1 | the difference in daily F tooth-brushing twice of
116 III, 10. 2. 1 | 2.1.5.1. Children Daily F Toothbrushing Frequency
117 III, 10. 2. 1 | AK, Kallestal C, Lagerlof F, Lingstrom P, Mejare I,
118 III, 10. 2. 1 | Bostrom G, Diderichsen F (1997): Socioeconomic differentials
119 III, 10. 2. 1 | Epidemiology 26:860–866.~ ~Branca F, Nikogosian H, Lobstein
120 III, 10. 2. 1 | October 2007).~ ~Branca F, Nikogosian H, Lobstein
121 III, 10. 2. 1 | Nutrition 61:743-751.~ ~Paccaud F, Wietlisbach V, Rickenbach
122 III, 10. 2. 1 | Rodler I, Bíró L, Greiner F, Zajkás G, Szórád I, Varga
123 III, 10. 2. 1 | Castetbon K, Arnault N, Bellisle F, Romano MC, Lehingue Y,
124 III, 10. 2. 1 | Darnton-Hill I, Delange F. Iodine deficiency in Europe:
125 III, 10. 2. 1 | Overvad K, Clavel-Chapelon F, Casagrande C, Riboli E (
126 III, 10. 2. 1 | E, Zavitsanos X, Berrino F, Sacerdote C, Ocke MC, Peeters
127 III, 10. 2. 1 | Tjonneland A, Clavel-Chapelon F, Linseisen J, Schulz M,
128 III, 10. 2. 1 | Tjonneland A, Clavel-Chapelon F, Linseisen J, Haftenberger
129 III, 10. 2. 1 | Tjonneland A, Clavel-Chapelon F, Kesse E, Miller AB, Schulz
130 III, 10. 2. 1 | Tjonneland A, Clavel-Chapelon F, Miller AB, Klipstein-Grobusch
131 III, 10. 2. 1 | Stripp C, Clavel-Chapelon F, Kesse E, Boeing H, Klipstein-Grobusch
132 III, 10. 2. 1 | Tjonneland A, Clavel-Chapelon F, Thiebaut A, Miller AB,
133 III, 10. 2. 1 | Tjonneland A, Clavel-Chapelon F, Linseisen J, Klipstein-Grobusch
134 III, 10. 2. 4 | Wichmann H E, Wienker T F, Schulze J, Schwarz P E,
135 III, 10. 2. 4 | Zuber M, Köchli OR, Mross F, Dieterich H, Moch H, Mihatsch
136 III, 10. 3. 1 | divided into frequency (f) bands, namely: radio frequency (
137 III, 10. 3. 1 | Fields (RF fields, 100 kHz <f 300 GHz), including epidemiologic,
138 III, 10. 3. 1 | Fields, (IF fields, 300 Hz <f 100 kHz), experimental and
139 III, 10. 3. 1 | magnetic fields (ELF, 0<f 300 Hz) the previous conclusion
140 III, 10. 3. 1 | 2006, Tampere, 2006.~Bray F, Sankila R, Ferlay J, Parkin
141 III, 10. 3. 1 | JM, Baysson H, Bochicchio F, Deo H, Falk R, Forastiere
142 III, 10. 3. 1 | Deo H, Falk R, Forastiere F, Hakama M, Heid I, Kreienbrock
143 III, 10. 3. 1 | Kreienbrock L, Kreuzer M, Lagarde F, Mäkeläinen I, Muirhead
144 III, 10. 3. 2 | Ma, S Caroli, A Alimonti, F Petrucci, B Bocca, P Schramel,
145 III, 10. 4. 1 | 2005.~ ~Holland, M.,Hurley, F., Pye S., Watkiss P. and
146 III, 10. 4. 2 | in case of emergencies; f) consumer information as
147 III, 10. 4. 2(40)| Commission f the European Communities:
148 III, 10. 4. 2 | for in this Regulation; (f) that they have contingency
149 III, 10. 4. 2 | Inoue, K, Okada, F, Ito, R, Kato, S, Sasaki,
150 III, 10. 4. 2 | Uno, A, Saijo, Y, Sata, F, Yoshimura, Y, Kishi, R,
151 III, 10. 4. 3 | Letters 164S: S324-S325~Valent F, et al (2004): Burden of
152 III, 10. 5. 1 | 15:67.~Miller DM, Meek F, (2004): Cost and efficacy
153 IV, 11. 6. 5 | Perleth M, Drummond M, Gürtner F, Jørgensen T, Jovell A,
154 IV, 11. 6. 5 | 2007.~ ~Gosden T, Forland F et al. (2006): Cochrane
155 IV, 12. 10 | warning’’ (ESA AO/1-4914/05/F/IZ, Duration: 01/07/2006-
|
|
| |
